Herpes simplex DNA vaccine - Vical

Drug Profile

Herpes simplex DNA vaccine - Vical

Alternative Names: HSV-2 DNA vaccine - Vical; HSV-2 glycoprotein D vaccine - Vical; VCL-HB01; VCL-HM01

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vical
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Herpes simplex virus infections

Most Recent Events

  • 19 Apr 2017 Vical completes enrolment in a phase II clinical trial for Herpes simplex virus infections in USA (NCT02837575) (IM)
  • 27 Sep 2016 Phase-II clinical trials in Herpes simplex virus infections (In adults) in USA (IM) (NCT02837575)
  • 20 Jun 2016 Efficacy and adverse events data from a phase I/II trial in Herpes simplex virus infections released by Vical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top